Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
8.53
-0.74 (-7.98%)
Jun 5, 2026, 1:49 PM EDT - Market open
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$989,491
Market Cap
625.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| CorMedix | 191 |
| Cabaletta Bio | 158 |
| Solid Biosciences | 121 |
| Aclaris Therapeutics | 73 |
| Alto Neuroscience | 68 |
| Zevra Therapeutics | 61 |
| Design Therapeutics | 54 |
CADL News
- 1 day ago - Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene - TheFly
- 3 days ago - Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire
- 3 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 17 days ago - Candel Therapeutics price target raised to $9 from $7 at BofA - TheFly
- 20 days ago - Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting - GlobeNewsWire
- 21 days ago - Candel Therapeutics Transcript: Study result - Transcripts